Current developments in peanut allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 3, 2006, Pages 202-206

  Palmer, Kricia ^a   Burks, Wesley ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allergen specific immunotherapy; Food allergy; Mutated allergen; Peanut hypersensitivity; Peanut sensitization

Indexed keywords

ANTIALLERGIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; FOOD ALLERGEN; FOOD ALLERGY HERBAL FORMULA 1; FOOD ALLERGY HERBAL FORMULA 2; HERBACEOUS AGENT; IMMUNOGLOBULIN E ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LYSOZYME; OMALIZUMAB; PEANUT ANTIGEN; PLASMID DNA; RECOMBINANT DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ALLERGEN; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; DNA VACCINE; LEUKOCYTE ANTIGEN;

CHINESE MEDICINE; CLINICAL TRIAL; DRUG EFFICACY; FOOD ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; NONHUMAN; PEANUT; PEANUT ALLERGY; PREDICTION; PRICK TEST; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TH1 CELL; TREATMENT OUTCOME; DESENSITIZATION; IMMUNOLOGY; PHYSIOLOGY;

ALLERGENS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ARACHIS HYPOGAEA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNIZATION; MEDICINE, CHINESE TRADITIONAL; PEANUT HYPERSENSITIVITY; VACCINES, DNA;

EID: 33745524175     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000225161.60274.31     Document Type: Review

References (43)

1. Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003;112:1203-1207.
2. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191-193.
3. Fleischer DM, Conover-Walker MK, Christie L, et al. The natural progression of peanut allergy: resolution and the possibility of recurrence. J Allergy Clin Immunol 2003; 112:183-189.
4. Li XM, Serebrisky D, Lee SY, et al. A murine model of peanut anaphylaxis: T-and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 2000; 106:150-158.
5. Adel-Patient K, Bernard H, Ah-Leung S, et al. Peanut- and cow's milk-specific IgE, Th2 cells and local anaphylactic reaction are induced in Balb/c mice orally sensitized with cholera toxin. Allergy 2005; 60:658-664.
6. Strid J, Thomson M, Hourihane J, et al. A novel model of sensitization and oral tolerance to peanut protein. Immunology 2004; 113:293-303.
7. Van Wijk F, Hartgring S, Koppelman SJ, et al. Mixed antibody and T cell responses to peanut and the peanut allergens Ara h 1, Ara h 2, Ara h 3 and Ara h 6 in an oral sensitization model. Clin Exp Allergy 2004; 34:1422-1428. An interesting study which shows that peanut sensitization may be a combined Th1/Th2 process.
8. Van Wijk F, Hoeks S, Nierkens S, et al. CTLA-4 signaling regulates the intensity of hypersensitivity responses to food antigens, but is not decisive in the induction of sensitization. J Immunol 2005; 174:174-179. In addition to elucidating the role of CTLA-4 in peanut sensitization, this study supports the hypothesis that sensitization is a combined Th1/Th2 process.
9. Van Wijk F, Nierkens S, Hassing I, et al. The effect of the food matrix on in vivo immune responses to purified peanut allergens. Toxicol Sci 2005; 86:333-341. An important study in context of the development of novel therapies for peanut allergy.
10. Burks AW, Cockrell G, Stanley JS, et al. Recombinant peanut allergen Ara h 1 expression and IgE binding in patients with peanut hypersensitivity. J Clin Invest 1995; 96:1715-1721.
11. Stanley JS, King N, Burks AW, et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys 1997; 342:244-253.
12. Koppelman SJ, Knol Ef, Vlooswijk RAA, et al. Peanut allergen Ara h 3: Isolation from peanuts and biochemical characterization. Allergy 2003; 58:1144-1151.
13. Burks AW, Sampson HA, Bannon GA. Peanut allergens. Allergy 1998; 53:725-730.
14. Rabjohn P, Helm EM, Stanley JS, et al. Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999; 103:535-542.
15. Restani P, Ballabio C, Corsini E, et al. Identification of the basic subunit of Ara h 3 as the major allergen in a group of children allergic to peanuts. Ann Allergy Asthma Immunol 2005; 94:262-266.
16. Lewis SA, Grimshaw EC, Warner JO, Hourihane JO. The promiscuity of immunoglobulin E binding to peanut allergens, as determined by Western blotting, correlates with the severity of clinical symptoms. Clin Exp Allergy 2005; 35:767-773. This article discusses interesting implications of the correlation between diversity of IgE binding and clinical severity.
17. Shreffler WG, Beyer K, Chu TT, et al. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J Allergy Clin Immunol 2004; 113:776-782. One of the first studies to identify a correlation between diversity of IgE binding and clinical severity.
18. Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90:256-262.
19. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99:744-751.
20. Li XM, Zhang TF, Huang CK, et al. Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 2001; 108:639-646.
21. Srivastava KD, Kattan JD, Zou ZM, et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 2005; 115:171-178. This paper provides evidence that a simplified formula is just as safe and effective in preventing peanut-induced anaphylaxis in mice.
22. Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance induced in naïve and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Natl Acad Sci USA 1993; 90:7608-7612.
23. Oldfield WLG. Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial. Lancet 2002; 360:47-53.
24. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-1628.
25. Glaspole IN, De Leon MP, Rolland JM, O'Hehir RE. Characterization of the T-cell epitopes of a major peanut allergen, Ara h 2. Allergy 2005; 60:35-40.
26. Hong SJ, Michael JG, Fehringer A, Leung DYM. Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes. J Allergy Clin Immunol 1999; 104:473-477.
27. Burks W, King N, Bannon GA. Modification of a major peanut allergen leads to loss of IgE binding. Int Arch Allergy Immunol 1999; 118:313-314.
28. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001; 124:70-72.
29. Rabjohn P, West CM, Connaughton C, et al. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 2002; 128:15-23.
30. King N, Helm R, Stanley JS, et al. Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res 2005; 49:963-971.
31. Bolhaar STHP, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004; 34:761-769.
32. Pons L, Ponnappan U, Hall RA, et al. Soy immunotherapy for peanut-allergic mice: modulation of the peanut-allergic response. J Allergy Clin Immunol 2004; 114:915-921. An interesting application of the use of homologous proteins in peanut immunotherapy.
33. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-855.
34. Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186:1623-1631.
35. Bohle B, Jahn-Schmid B, Maurer D, et al. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18, and IFNγ production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999; 29:2344-2353.
36. Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol 1998; 161:4146-4152.
37. Li XM, Srivastava K, Huleatt JW, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 2003; 170:3289-3295.
38. Frick OL, Teuber SS, Buchanan BB, et al. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs. Allergy 2005; 60:243-250. Demonstrates the efficacy of HKLM as an adjuvant in mammals.
39. Spiegelberg HL, Orozco EM, Roman M, Raz E. DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997; 52:964-970.
40. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2:540-544.
41. Broide D, Orozco EM, Roman M, et al. Intradermal gene vaccination downregulates both arms of the allergic response. J Allergy Clin Immunol 1997; 99:S129.
42. Hengge UR, Walker PS, Vogel JC. Expression of naked DNA in human, pig and mouse skin. J Clin Invest 1996; 97:2911-2916.
43. Leung DYM, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993.